Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Exhibit 1.1
- 4.4 Exhibit 4.4
- 4.6 Exhibit 4.6
- 4.10 Exhibit 4.10
- 4.11 Exhibit 4.11
- 4.14 Exhibit 4.14
- 4.15 Exhibit 4.15
- 4.16 Exhibit 4.16
- 4.17 Exhibit 4.17
- 4.18 Exhibit 4.18
- 4.19 Exhibit 4.19
- 4.20 Exhibit 4.20
- 4.21 Exhibit 4.21
- 4.22 Exhibit 4.22
- 4.23 Exhibit 4.23
- 4.24 Exhibit 4.24
- 4.25 Exhibit 4.25
- 4.27 Exhibit 4.27
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13 Exhibit 13
- 15.1 Exhibit 15.1
RDHL similar filings
Filing view
External links
Exhibit 13
CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of RedHill Biopharma Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to such officer's knowledge:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: February 25, 2015
/s/ Dror Ben-Asher |
Dror Ben-Asher |
Chief Executive Officer |
/s/ Ori Shilo |
Ori Shilo |
Deputy Chief Executive Officer Finance and Operations |